Research programme: dopamine transporter targeted imaging agents - Alseres

Drug Profile

Research programme: dopamine transporter targeted imaging agents - Alseres

Alternative Names: O 1505; O 1505T

Latest Information Update: 12 May 2011

Price : $50

At a glance

  • Originator Harvard University
  • Developer Alseres Pharmaceuticals
  • Class Imaging agents
  • Mechanism of Action Dopamine plasma membrane transport protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 14 Sep 2007 Preclinical development is ongoing
  • 08 Jun 2007 Boston Life Sciences is now called Alseres Pharmaceuticals
  • 17 Aug 2005 Preclinical trials in Parkinson's disease and Atttention-deficit hyperactivity disorder diagnosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top